Doramapimod

N/A

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameDoramapimod
Drug Alias Name多玛莫德doramapimodum度马莫德达马莫德BIRB-796-BS +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitorsTumor necrosis factor α inhibitors
TargetsP38 mitogen-activated protein kinaseTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsPsoriasisArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksKEGG